

REMARKS

This response is filed concurrently with a Request for Continued Examination. Claims 2-3 and 48-60 are pending. Claims 1 and 4-47 have been cancelled.

Applicants acknowledge the Examiner's allowance of claims 2 and 3.

In view of the cancellation of claim 5, the Examiner's objection to this claim is now moot.

In view of the cancellation of claim 7, the Examiner's objection to this claim is also now moot.

Claim 48 has been amended such that R³ no longer includes "aryl optionally substituted by one or more R⁶, heteroaryl optionally substituted by one or more R⁶ⁿ". Therefore, claim 48 and the claims that depend from it, as amended, do not have Ar² as defined by Burkholder (WO94/26735). Accordingly, it is respectfully requested that this rejection of the claims under 35 USC § 103(a) be reconsidered and withdrawn.


The claim objection in which claims 4, 7, 10-12, 15, 25, 29, and 43 are objected to because they depend on claim 48, a subsequent claim, is believed to be moot in view of the claims Applicants have submitted in this response. Hence, it is respectfully requested that this objection be reconsidered and removed.

There is a Supplemental Information Disclosure Statement filed concurrently with this correspondence.

In view of the foregoing amendments and remarks, it is respectfully requested that the claims be reconsidered and allowed.

Respectfully submitted,

Date: 22 March 2002


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988